Compound profile
Also known as: Body Protection Compound-157 · PL 14736
A synthetic peptide fragment derived from a gastric protein, widely discussed for soft-tissue recovery. Human evidence remains limited relative to its online popularity.
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, whose sequence is drawn from a larger protective protein found in human gastric juice. The name is short for "body protection compound," and the "157" refers to its position in that parent sequence. Researchers at the University of Zagreb, led by Predrag Sikiric, first described the peptide's protective effects on the gut lining in the early 1990s, and most of the research base since then has stayed close to that origin: animal and cell studies of tissue protection and repair.
Outside the lab, BPC-157 has become one of the most talked about research peptides in fitness and recovery circles, where it is discussed for tendon, ligament, muscle, and gut healing. That popularity runs well ahead of the human evidence. Almost everything published on BPC-157 comes from animal models, cell cultures, or review articles synthesizing that preclinical work, not controlled human trials.
Its regulatory status reflects that gap. BPC-157 has never been approved by the FDA as a drug, and compounding pharmacies have been restricted from preparing it under bulk substance rules. In 2026 the FDA removed it from its Category 2 restricted list without moving it to the approved Category 1 list, leaving it in a regulatory gray area, neither cleared for compounding nor explicitly banned. It is sold, when it is sold, as a research chemical, not as a medicine.
Preclinical work explores effects on angiogenesis, nitric oxide pathways, and tissue healing signals. Precise human mechanisms are not settled.
Most of what is known about how BPC-157 works comes from animal and cell-based research, and the mechanism is still being pieced together rather than settled. The leading hypothesis centers on angiogenesis, the growth of new blood vessels, with studies pointing to activity along the VEGFR2 signaling pathway and FAK-paxillin interactions that help endothelial cells migrate and form new vessels at injury sites. Faster blood vessel formation is one proposed reason the peptide shows healing effects across such a wide range of tissue types in animal models.
A second thread of research looks at the nitric oxide (NO) system, which BPC-157 appears to modulate in ways researchers describe as protective, helping maintain healthy NO signaling while blunting some of its more damaging effects during tissue injury. Separate preclinical work has reported increased growth hormone receptor expression in tendon fibroblasts, offering one possible explanation for its reputation in tendon and ligament research. Other proposed pathways include Egr-1 transcription factor activity and Akt/PI3K survival signaling in cells under stress. None of these mechanisms has been confirmed in controlled human studies, so they should be read as preclinical hypotheses, not settled human pharmacology.
Animal and in-vitro studies report wound-healing and gut-protection signals. Fitness communities extrapolate to tendon, ligament, and gut recovery, but those extrapolations outpace high-quality human trials.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Animal studies report faster healing of tendons, ligaments, muscle, and skin wounds, an effect frequently linked back to increased blood vessel growth (angiogenesis) at the injury site.
The original research line: preclinical models report protective effects on the stomach lining, including faster healing of induced ulcers and better resistance to GI injury, which is where the compound's name comes from.
A study in tendon fibroblasts found increased expression of growth hormone receptors after BPC-157 exposure, a proposed mechanism behind its tendon-healing reputation.
Reviews describe consistent effects on the nitric oxide system and vascular signaling pathways across multiple animal injury models, alongside reported anti-inflammatory activity.
Limited rigorous human RCTs for athletic injuries. Quality, purity, and legality of research chemicals vary. Unknown long-term safety profile in healthy athletes.
The evidence base for BPC-157 is overwhelmingly preclinical. The large majority of published studies are in rodents, other animal models, or cell culture, and controlled human trials for the injury and recovery uses it's discussed for online are scarce to nonexistent. That leaves a real gap between what animal data suggests and what has actually been demonstrated in people. Because it sits in a regulatory gray zone rather than being an approved or legally compounded drug, anyone encountering it as a research chemical is also relying on unregulated manufacturing, so purity, dosing accuracy, and contamination are practical concerns independent of the underlying biology. Long-term safety data in healthy humans does not exist.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Online communities often discuss GHK-Cu, BPC-157, and TB-500 together under the informal name “GLOW,” usually in the context of skin quality and soft-tissue recovery conversations, not as a single studied product.
GLOW is a community nickname, not a validated clinical protocol. There are no dose schedules here. Read each peptide’s evidence level and primary sources separately.
Skin / repair · Recovery
Commonly discussed together
BPC-157 and TB-500 are frequently mentioned side-by-side in recovery forums as a “commonly discussed together” pairing for soft-tissue talk, again as folklore adjacency, not a packaged regimen.
Preclinical literature for each compound does not equal a combined human protocol. No timelines or doses are provided on STACKD Research.
Recovery
